PI3K is one of the major molecules interacting with IGF-1R to regulate cell signaling; the mutation of PIK3CA can lead to tumorigenesis in the absence of the suppressor PTEN.106 This makes PI3K a potential target, but the pharmacodynamics of PI3K inhibitors in breast cancer patient is not yet known. This evidence concerns the gene PTEN and breast carcinoma.